
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX Inc. demonstrates a positive outlook due to the encouraging clinical results from its BX211 treatment for diabetic foot osteomyelitis (DFO), which showed significant improvements across several clinical parameters including infection resolution and reductions in C-Reactive Protein levels. Additionally, the positive feedback from the FDA regarding the advancement of the BX011 multi-phage cocktail into a Phase 2a study positions BiomX favorably for potential market expansion and improved patient outcomes in cystic fibrosis. The company’s strategy to explore additional indications and broader market applications, alongside potential regulatory advancements, suggests significant upside potential for future revenues.
Bears say
BiomX Inc faces a negative outlook primarily due to the mixed results from its clinical trials, where key endpoints narrowly missed statistical significance, leading to unfavorable investor sentiment. The company could struggle to secure adequate funding to support its drug development efforts, and challenges such as dilutive capital raises further exacerbate financial risks. Additionally, the potential for failed or inconclusive clinical outcomes may hinder its chances of achieving commercial success, contributing to the pessimistic view on its stock.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares